Skip to Content
Merck

Key Documents

View All Documentation

EHU099921

MISSION® esiRNA

targeting human PSMA7

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

TGATGGCACTCCTAGGCTCTATCAGACTGACCCCTCGGGCACATACCATGCCTGGAAGGCCAATGCCATAGGTCGGGGTGCCAAGTCAGTGCGCGAGTTCCTGGAGAAGAACTATACTGACGAAGCCATTGAAACAGATGATCTGACCATTAAGCTGGTGATCAAGGCACTCCTGGAAGTGGTTCAGTCAGGTGGCAAAAACATTGAACTTGCTGTCATGAGGC

Ensembl | human accession no.

ENSG00000101182

NCBI accession no.

NM_002792

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... PSMA7(5688)

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
ZYU
OWU

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chen-Chen Ren et al.
Journal of cellular physiology, 234(5), 5851-5862 (2017-12-17)
This study aims to evaluate the effects of PSMA7 silencing on cervical cancer (CC) cell proliferation and vascular endothelial growth factor (VEGF) expression through the ubiquitin-proteasome pathway. CC tissues (n = 43) and normal tissues (n = 27) were first collected from patients. Human